fashion -WSS

fashion

author：Wikipedia 2025-09-30 18:54:45 - browse：364

Christopher Boerner -- biotech JPM coverage from STAT — Bristol CEO Christopher Boerner Business Wire via AP

SAN FRANCISCO — Christopher Boerner has been the CEO of Bristol Myers Squibb for just two months. But in trying to sell the company to investors on Monday at the annual J.P. Morgan Healthcare Conference, he pointed to the company’s 150-year history.

He spoke of the “next chapter” for BMS, which saw its stock fall 27% last year, and said that the company would be going through a “period of renewal.” Basically, the tide comes in, but it also goes out. Patents on big-selling medicines expire, but new medicines will come to take their place.

Investors may not be able to view those changes with equanimity. Sales of Bristol’s top sellers will decline significantly or vanish as generic or biosimilar medicines emerge. That includes Eliquis, the blood thinner for stroke prevention that will be one of the first medications subject to price negotiation under the Inflation Reduction Act; Revlimid, the best-selling multiple myeloma medicine that Bristol acquired when it bought Celgene for $74 billion in 2019; and Opdivo, Bristol’s pioneering cancer immunotherapy, which is an $8 billion seller.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Supreme Court strikes down use of affirmative action
Next article： Study identifies new proteins linked to dementia risk 25 years later

hotspot

entertainment

hotspot

WSS

Can food be medicine? And other questions about a new push

Listen: Biogen's messy board & Laronde's data problem

Van's Gluten Free Original Waffles recalled for possible wheat allergen

Doctor appointment wait times are getting worse

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

Inside the fall of star MIT scientist David Sabatini

leisure time

fashion

focus

As demand for Covid shots wanes, Moderna seeks its next success

Listen: PBM conflicts, RSV vaccines, & the future of flu season

Apple is now the first public company to be valued at $3 trillion

Judge rejects Trump's request to move Stormy Daniels hush

Medical leaders decry Supreme Court decision on affirmative action

Community addresses injustice for Long Island mothers

DIEP, the 'gold standard' of breast reconstruction, is under threat

Tesla recalling nearly 16,000 of its 2021

United colonoscopy coverage change 'may cost lives,' doctors say

Study identifies new proteins linked to dementia risk 25 years later

https://cbu01.alicdn.com/img/ibank/2015/448/156/2330651844_715837672.220x220xz.jpg

Option Care buys Amedisys in $3.6 billion home care deal

I learned firsthand about improving diversity in clinical trials

Tocagen's brain cancer gene therapy trial continues. Investors worry

Why is France rioting? What to know about the fatal police shooting of Nahel M

Winning ticket for $1 billion Powerball jackpot sold in California

Affordable Connectivity Program vital to health care, experts say

hotspot

entertainment

hotspot

entertainment